<DOC>
	<DOCNO>NCT01657331</DOCNO>
	<brief_summary>This phase 1/2 multicenter study assess safety effectiveness brentuximab vedotin bendamustine , give together , patient Hodgkin Lymphoma Anaplastic Large Cell Lymphoma ( ALCL ) either return respond initial treatment ( ) . Patients accrue Columbia University Medical Center ( CUMC ) two subsites Canada .</brief_summary>
	<brief_title>Brentuximab Vedotin Bendamustine Treatment Hodgkin Lymphoma Anaplastic Large Cell Lymphoma ( ALCL )</brief_title>
	<detailed_description>Brentuximab vedotin administer outpatient IV infusion day 1 21-day cycle . Bendamustine give outpatient infusion day 1 2 21-day cycle . Patients may receive prophylactic pegfilgrastim day 3 cycle , filgrastim 5 10 day , per investigator 's discretion . Patients receive maximum 6 cycle therapy .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Histologically confirm relapsed refractory HL ALCL . Documented CD30+ expression either original diagnosis tumor biopsy relapse setting . For patient HL , subject eligible failure decline autologous stem cell transplant least two prior multiagent chemotherapy regimens autologous stem cell transplant candidate . For patient ALCL , subject eligible failure least one prior multiagent chemotherapy regimen eligible decline autologous stem cell transplant . Must receive first line chemotherapy . No upper limit number prior therapy . Patients prior autologous allogeneic stem cell transplant eligible long meet criterion . Measurable evaluable disease , defined 2008 Revised Response Criteria Malignant Lymphoma ( 33 ) Age &gt; = 18 year ECOG performance status 0,1 2 Patient 's must adequate organ marrow function define Absolute neutrophil count &gt; = 1,000 ( 1.0 x 109/L ) Platelets &gt; = 50,000 ( 50 x 109/L ) Total Bilirubin &lt; = 1.5 x institutional limit unless document Gilbert 's syndrome ( &lt; 2.5 x institutional upper limit ) AST ( SGOT ) /ALT ( SGPT ) &lt; = 2.0 x institutional upper limit normal ( unless know hepatic involvement &lt; 3.5 x institutional upper limit ) Creatinine within normal institutional limit OR creatinine clearance &gt; = 50mL/min patient creatinine level institutional normal If female childbearing age , negative serum pregnancy test within 7 day prior first dose brentuximab vedotin study Must willing use contraception study , 30 day follow last dose study drug . Able understand sign write consent document Prior treatment brentuximab vedotin bendamustine combination . May receive prior therapy brentuximab vedotin bendamustine separately . Received either brentuximab vedotin bendamustine within 3 month receive first dose protocol base therapy . If brentuximab vedotin bendamustine previously receive , disease progression first 3 cycle either brentuximab vedotin bendamustine . Systemic steroid stabilize equivalent &lt; 10 mg/day prednisone 7 day prior initiation trial . ANY concurrent investigational agent . Exposure chemotherapy , radiotherapy , biologics investigational agent within 3 week prior enrollment study . Known cerebral meningeal disease . Active concurrent malignancy ( except nonmelanoma skin cancer carcinoma situ cervix ) . If history prior malignancy patient must disease free treatment &gt; = 3 year . Uncontrolled intercurrent illness include limited : ongoing active infection , systemic congestive heart failure Class III IV NYHA criterion , unstable angina pectoris , cardiac arrhythmia , patient status post allogeneic transplantation uncontrolled graft versus host disease ( GVHD ) . Preexisting neuropathy grade III great . Pregnant nursing . Known hypersensitivity brentuximab vedotin , bendamustine , mannitol . Known Human Immunodeficiency Virus ( HIV ) positive , hepatitis A , hepatitis B hepatitis C ; hepatitis Bsurface antigen positive Bcore antibody positive must normal liver function test willing able take antihepatitis medication lamivudine equivalent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hodgkin Lymphoma</keyword>
	<keyword>Hodgkin Disease</keyword>
	<keyword>Hodgkin 's Disease</keyword>
	<keyword>Anaplastic Large Cell Lymphoma</keyword>
	<keyword>ALCL</keyword>
	<keyword>SGN+Benda</keyword>
	<keyword>Bendamustine</keyword>
	<keyword>Brentuximab Vedotin</keyword>
</DOC>